GLP-1 Skincare Becomes a Sub-Category: TikTok Data and Clinical Evidence Are Now Aligned

British Beauty Council and WGSN circulated a formal category brief to brand partners on approximately April 30, 2026, detailing GLP-1 impacts on skin, hair, and fragrance. This is a strategic planning document, not a trend report. Simultaneously, LovelySkin published a clinical ingredient guide on May 3 covering NAD+, firming actives, and barrier-repair formulations specifically for GLP-1 users.

The numbers that move the category from trend to sub-category: 1 in 8 US adults now use GLP-1 medications, 30 million Americans projected by 2030, UK adoption has nearly doubled in a year to ~1 in 10 consumers, McKinsey research shows 82% of GLP-1 users express concern about loose skin and loss of firmness, and TikTok views for #GLP1hairloss are up 665%. A 2025 Vanderbilt University study (PMID 40407186) documented a median 9% decrease in total midfacial volume in GLP-1 patients.

WGSN Senior Beauty Strategist Pia Fisher, speaking at the BBC briefing, confirmed the formulation shift: GLP-1 usage is pushing skincare toward "tweakment-grade" formats — NAD+ and NMN for cellular energy restoration, PDRN and exosomes for tissue repair, and EMS/microcurrent device integration into topical regimes. Fragrance is also affected: "neo-gourmand" formats are emerging as food-adjacent sensory substitutes, and a "no-fragrance fragrance" sub-category is developing for users with heightened scent sensitivity. NutraIngredients reported in March that brands are recruiting GLP-1 users directly into clinical trials to substantiate skin-change claims.

The counter-signal matters. WGSN names a parallel trend — "Fauxzempic" — for the consumers who reject or cannot afford GLP-1s, driving demand for lymphatic tools, ear seeding, and systems-based wellness. Any brand formulating for GLP-1 users needs a counter-narrative for the 72% of the market not on them. The brands moving credibly here — Augustinus Bader, Dr. Barbara Sturm, the clinical end of K-beauty — already have the actives architecture. The opening is for the next clean-positioned brand to publish a clinically credentialed GLP-1 protocol without overclaiming.